Cargando…

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine

INTRODUCTION: : Cariprazine, a dopamine D(3)-preferring D(3)/D(2) receptor partial agonist and serotonin 5-HT(1A) receptor partial agonist, has two major human metabolites, desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR). The metabolite pharmacology was profiled to understand the co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiss, Béla, Némethy, Zsolt, Fazekas, Károly, Kurkó, Dalma, Gyertyán, István, Sághy, Katalin, Laszlovszky, István, Farkas, Bence, Kirschner, Norbert, Bolf-Terjéki, Etelka, Balázs, Ottilia, Lendvai, Balázs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754336/ https://www.ncbi.nlm.nih.gov/pubmed/31571826 http://dx.doi.org/10.2147/DDDT.S188760

Ejemplares similares

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021)

Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder
por: Román, Viktor, et al.
Publicado: (2021)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
por: Durgam, Suresh, et al.
Publicado: (2016)

The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task
por: Barnes, Samuel A., et al.
Publicado: (2018)

Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
por: Kiss, Béla, et al.
Publicado: (2021)

The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices
por: Meier, Maria A., et al.
Publicado: (2020)

Correction to: The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task
por: Barnes, Samuel A., et al.
Publicado: (2018)

Cariprazine Exhibits Anxiolytic and Dopamine D(3) Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
por: Duric, Vanja, et al.
Publicado: (2017)

Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D(3) Receptors in the Brain in vivo
por: Kiss, Béla, et al.
Publicado: (2022)

Cariprazine exerts antimanic properties and interferes with dopamine D(2) receptor β-arrestin interactions
por: Gao, Yonglin, et al.
Publicado: (2015)

Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity
por: Kehr, Jan, et al.
Publicado: (2018)

Converging Evidence on D-Amino Acid Oxidase–Dependent Enhancement of Hippocampal Firing Activity and Passive Avoidance Learning in Rats
por: Nagy, Lili Veronika, et al.
Publicado: (2020)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
por: Earley, Willie, et al.
Publicado: (2017)

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
por: Durgam, Suresh, et al.
Publicado: (2016)

The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
por: Delcourte, Sarah, et al.
Publicado: (2018)

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2019)

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
por: Culpepper, Larry, et al.
Publicado: (2022)

Preferential binding to dopamine D(3) over D(2) receptors by cariprazine in patients with schizophrenia using PET with the D(3)/D(2) receptor ligand [(11)C]-(+)-PHNO
por: Girgis, Ragy R., et al.
Publicado: (2016)

Cariprazine pharmacokinetics
Publicado: (2022)

Search for novel antipsychotic drugs: dopamine forever?
por: Gyertyán, István
Publicado: (2009)

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D(3) Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders
por: Kehr, Jan, et al.
Publicado: (2022)

The Histological Changes of the Great Saphenous Vein at 2 Years after Cryosclerosis
por: Balint, Istvan Bence, et al.
Publicado: (2014)

Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment
por: Molnar, Maria Judit, et al.
Publicado: (2022)

Safety during polypharmacy: A post-hoc analysis examining the safety profile of cariprazine with other antipsychotics in the cross-titration phase
por: Vass, G., et al.
Publicado: (2021)

The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
por: Laszlovszky, I., et al.
Publicado: (2021)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms
por: Demyttenaere, Koen, et al.
Publicado: (2021)

The improvement of motor symptoms in Huntington’s disease during cariprazine treatment
por: Csehi, Reka, et al.
Publicado: (2023)

Preseptal cellulitis and infraorbital abscess as a complication of a routine COVID-19 swab
por: Fazekas, Balazs, et al.
Publicado: (2021)

Contribution of analog signaling to neurotransmitter interactions and behavior: Role of transporter‐mediated nonquantal dopamine release
por: Román, Viktor, et al.
Publicado: (2021)

Open Source Tools for Temporally Controlled Rodent Behavior Suitable for Electrophysiology and Optogenetic Manipulations
por: Solari, Nicola, et al.
Publicado: (2018)

Response-related sensorimotor rhythms under scopolamine and MK-801 exposures in the touchscreen visual discrimination test in rats
por: Kostyalik, Diána, et al.
Publicado: (2022)

High temporal resolution Nanopore sequencing dataset of SARS-CoV-2 and host cell RNAs
por: Tombácz, Dóra, et al.
Publicado: (2022)

Maternal cariprazine exposure inhibits embryonic and postnatal brain cholesterol biosynthesis
por: Genaro-Mattos, Thiago C., et al.
Publicado: (2020)

Effects of Cariprazine, Aripiprazole, and Olanzapine on Mouse Fibroblast Culture: Changes in Adiponectin Contents in Supernatants, Triglyceride Accumulation, and Peroxisome Proliferator-Activated Receptor-γ Expression
por: Bába, László-István, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1mvklvmcf1uouqk39bo646g0cq